

## Annexure-I

### Annexure – I: Preformulation Study

<p>Company Logo Here</p> <p><b>XX PHARMACEUTICALS LIMITED</b></p> <p>117 Adams Street, Brooklyn, NY 11201, USA</p>
--

<b>Product Name:</b>			
<b>1. ACTIVE PHARMACEUTICALS INGREDIENT STUDIES</b>			
<b>PHYSICOCHEMICAL PROPERTIES</b>			
<b>STRUCTURE</b>		<b>EMPIRICAL FORMULA</b>	
<b>IUPAC NAME</b>		<b>MOLECULAR WEIGHT</b>	
<b>PERCENT COMPOSITION BY ELEMENT(In mass)</b>			
<b>MOLECULE TYPE</b>			
<b>SOLUBILITY</b>			
<b>CONTENT</b>			
<b>HYGROSCOPICITY</b>			
<b>MELTING POINT</b>			
<b>POLYMORPHISM</b>			
<b>APPEARANCE</b>			
<b>IMPURITIES</b>			
<b>PHARMACOLOGY</b>			
<b>USE</b>			
<b>ACTION</b>			
<b>TARGET</b>			
<b>ABSORPTION</b>			

<b>VOLUME OF DISTRIBUTION</b>	
<b>SPECIFIC FUNCTION</b>	
<b>PROTEIN BINDING</b>	
<b>METABOLISM</b>	
<b>ROUTE OF ELEMINATION</b>	
<b>HALF LIFE</b>	
<b>TOXICITY</b>	
<b>DRUG INTERACTION</b>	

www.pharmaguideline.co.uk